These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33557653)

  • 1. Hepatocyte and immune cell crosstalk in non-alcoholic fatty liver disease.
    Carranza-Trejo AM; Vetvicka V; Vistejnova L; Kralickova M; Montufar EB
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):783-796. PubMed ID: 33557653
    [No Abstract]   [Full Text] [Related]  

  • 2. Adaptive immunity: an emerging player in the progression of NAFLD.
    Sutti S; Albano E
    Nat Rev Gastroenterol Hepatol; 2020 Feb; 17(2):81-92. PubMed ID: 31605031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
    Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y
    J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis.
    Cai J; Zhang XJ; Li H
    Hepatology; 2019 Sep; 70(3):1026-1037. PubMed ID: 30653691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells.
    Magee N; Zou A; Zhang Y
    Biomed Res Int; 2016; 2016():5170402. PubMed ID: 27822476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH).
    Nati M; Haddad D; Birkenfeld AL; Koch CA; Chavakis T; Chatzigeorgiou A
    Rev Endocr Metab Disord; 2016 Mar; 17(1):29-39. PubMed ID: 26847547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innate Immunity and Inflammation in NAFLD/NASH.
    Arrese M; Cabrera D; Kalergis AM; Feldstein AE
    Dig Dis Sci; 2016 May; 61(5):1294-303. PubMed ID: 26841783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: a 2015 update.
    Sutti S; Bruzzì S; Albano E
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):243-53. PubMed ID: 26634783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of Hepatic Innate and Innate-Like Lymphocytes in Nonalcoholic Steatohepatitis.
    Chen Y; Tian Z
    Front Immunol; 2020; 11():1500. PubMed ID: 32765518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Manne V; Handa P; Kowdley KV
    Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis?
    Handa P; Vemulakonda A; Kowdley KV; Uribe M; Méndez-Sánchez N
    World J Gastroenterol; 2016 Aug; 22(31):6965-71. PubMed ID: 27610009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling.
    Barrow F; Khan S; Fredrickson G; Wang H; Dietsche K; Parthiban P; Robert S; Kaiser T; Winer S; Herman A; Adeyi O; Mouzaki M; Khoruts A; Hogquist KA; Staley C; Winer DA; Revelo XS
    Hepatology; 2021 Aug; 74(2):704-722. PubMed ID: 33609303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease.
    Nati M; Chung KJ; Chavakis T
    J Innate Immun; 2022; 14(1):31-41. PubMed ID: 34515137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression.
    Dallio M; Sangineto M; Romeo M; Villani R; Romano AD; Loguercio C; Serviddio G; Federico A
    Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33406763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD).
    Bruzzì S; Sutti S; Giudici G; Burlone ME; Ramavath NN; Toscani A; Bozzola C; Schneider P; Morello E; Parola M; Pirisi M; Albano E
    Free Radic Biol Med; 2018 Aug; 124():249-259. PubMed ID: 29920340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
    Farrell GC; Haczeyni F; Chitturi S
    Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Lee C; Kim J; Jung Y
    Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kazankov K; Jørgensen SMD; Thomsen KL; Møller HJ; Vilstrup H; George J; Schuppan D; Grønbæk H
    Nat Rev Gastroenterol Hepatol; 2019 Mar; 16(3):145-159. PubMed ID: 30482910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NOD2 in hepatocytes engages a liver-gut axis to protect against steatosis, fibrosis, and gut dysbiosis during fatty liver disease in mice.
    Cavallari JF; Pokrajac NT; Zlitni S; Foley KP; Henriksbo BD; Schertzer JD
    Am J Physiol Endocrinol Metab; 2020 Aug; 319(2):E305-E314. PubMed ID: 32516028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.